Expression of Serum hs-CRP and Lp-PLA2 in Arrhythmia Patients and its Significance

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (4341 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: The purpose of this study is to examine the expression of serum high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) in patients with arrhythmia and its significance. Methods: We selected 136 arrhythmia patients (observation group) who were treated at our hospital from February 2016 to March 2018. Among these patients, 50 had premature ventricular contractions, 42 had atrial fibrillation, 24 had atrial flutter, and 20 had ventricular tachycardia. Simultaneously, we selected 120 healthy volunteers as the control group. We measured serum levels of hs-CRP and Lp-PLA2 in these subjects. Results: The levels of Lp-PLA2 and hs-CRP of the observation group were 210.06±30.46 pg/mL and 13.54±3.16, respectively, which were significantly higher than those of the control group (P<0.05). The serum levels of Lp-PLA2 and hs-CRP of patients with atrial flutter were 260.87±32.24 and 19.84±5.10 pg/mL, respectively, which were significantly higher than those of patients with premature ventricular contractions, atrial fibrillation, and ventricular tachycardia (P<0.05). Serum levels of Lp-PLA2 and hs-CRP were positively correlated (r=0.413, P<0.05). Conclusion: Serum levels of hs-CRP and Lp-PLA2 in arrhythmia patients were significantly elevated and showed some association with the type of arrhythmia.

Key words： high-sensitivity C-reactive protein lipoprotein-associated phospholipase A2 arrhythmia

Received: 20 April 2019

Corresponding Authors: CONG Xiu-feng. E-mail: cara_cong@163.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CONG Xiu-feng

Cite this article:

CONG Xiu-feng. Expression of Serum hs-CRP and Lp-PLA2 in Arrhythmia Patients and its Significance[J]. Chinese Journal of Biomedical Engineering, 2019, 28(2): 66-71.

URL:

http://manu32.magtech.com.cn/Jwk_zgswyx_en/EN/ OR http://manu32.magtech.com.cn/Jwk_zgswyx_en/EN/Y2019/V28/I2/66

[1] Deng H, Bai Y, Shantsila A, et al.Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review[J]. Clinical Research in Cardiology,2017,106(10):813-823.
[2] Soltani G, Jahanbakhsh S, Abbasi Tashnizi M, et al.Effects of dexmedetomidine on heart arrhythmia prevention in off-pump coronary artery bypass surgery: A randomized clinical trial[J]. Electronic Physician,2017,9(10):5578-5587.
[3] Zhang XY, Jiang JP, Li YH. Analysis of the effects of amiodarone and psychological intervention in the treatment of arrhythmia and its effects on serum high sensitive C reactive protein [J]. Chinese Journal of Biochemical and Pharmaceuticals, 2017,37(10):56-58 [in Chinese].
[4] Yao JH. Clinical value of determining serum lipoprotein-associated phospholipase a2 and blood lipid levels in patients with diabetic coronary disease [J]. Chinese Journal of Hemorheology, 2015,25(1):89-92, 107. [in Chinese].
[5] B Schnabel R, Pecen L, Engler D, et al. Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes[J]. Heart,2018,104(19):1608-1614.
[6] Zheng R, Tian G, Zhang Q, et al.Clinical Safety and Efficacy of Wenxin Keli-Amiodarone Combination on Heart Failure Complicated by Ventricular Arrhythmia: A Systematic Review and Meta-analysis[J]. Frontiers in Physiology,2018,9(6):90-93.
[7] Elsokkari I, Parkash R, Gray C J, et al.Effect of coronary revascularization on long-term clinical outcomes in patients with ischemic cardiomyopathy and recurrent ventricular arrhythmia[J]. Pacing and Clinical Electrophysiology,2018,41(7):775-779.
[8] Zhang XJ. Analysis of clinical significance of plasma high sensitivity Creactive protein and type B brain natriuretic peptide in the diagnosis of malignant ventricular arrhythmias in hospitalized elderly patients with chronic heart failure [J]. Chinese Journal of Modern Drug Application, 2017,11(13):12-14. [in Chinese].
[9] Xiong QY, Zeng CJ, Cen JM, et al. Clinical significance of concentration of plasma lipoprotein-associated phospholipase A2 in different types of coronary heart disease [J]. China Journal of Modern Medicine, 2015,25(29):78-82. [in Chinese].
[10] Xu YF. Research of influence of amiodarone on serum high sensitivity C-reactive protein in the treatment of arrhythmia [J]. China Practical Medical, 2015,10(10):34-35 [in Chinese].
[11] Xu LH, Cheng ZF, Li GH, et al. The risk factor analysis of malignant arrhythmia after coronary intervention in patients with acute myocardial infarction [J]. Chinese Journal of Clinical Healthcare, 2018,21(2):199-202. [in Chinese].
[12] Peng D, Liu JH. Risk assessment method for ischemic arrhythmia [J]. Chinese Journal of Interventional Cardiology, 2017,25(6):343-346. [in Chinese].
[13] Lu L, Sun LS, Fan LY. Clinical application value of serum lipoprotein associated phospholipaseA2 in coronary atherosclerotic heart diseases [J]. International Journal of Laboratory Medicine, 2016,37(16):2247-2249. [in Chinese].
[14] Hao CY, Huang YY. Effects of amiodarone and propafenone on heart rate variability in elderly arrhythmia patients and high-sensitivity C-reactive protein [J]. Chinese Journal of Gerontology, 2018,38(6):1328-1330. [in Chinese].
[15] Liu ZJ, Li WZ, Yang D, et al. Effects of pulse pressure index and C-reactive protein on acute myocardial infarction patients with comorbid ventricular arrhythmia [J]. Journal of Mudanjiang Medical University, 2015,36(4):16-18. [in Chinese].